Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
... ccRCC and UC. The analysis included patients with stage IV ccRCC (15,926 individuals) or UC (10,380 individuals) identified from the National ...
Alexandra Drakaki, MD, PhD, discusses the potential role of zanzalintinib in advanced non–clear cell renal cell carcinoma.
Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Renal Cell Carcinoma.
Significant socioeconomic disparities exist for patients with advanced clear cell renal cell carcinoma and urothelial carcinoma of the bladder.
1. Median PFS (5.6 months vs 5.6 months) and median OS (21.4 months vs 18.1 months) were similar in both arms. 2. Treatment-related adverse events grade 3-5 occurred in 38.7% of the belzutifan group and 39.4% of the everolimus group. Evidence Rating Level: 1 (Excellent) Study Rundown: ...
Moshe Ornstein, MD, MA, discusses the use of first-line IO/TKI doublet regimens in patients with non–clear cell renal cell carcinoma.
There are remaining gaps in papillary renal cell carcinoma that data from 3 pending trials hope to fill.
Medical experts explore the main challenges in treating non–clear cell RCC compared with clear cell RCC, discussing how these difficulties vary between community and academic settings.
In this Perspective, the authors provide an overview of the most promising deregulated non-coding RNAs in clear-cell renal cell carcinoma, discussing the role of different classes of non-coding RNAs in clear-cell renal cell carcinoma development and progression. Future perspectives and ...
Findings from a subgroup analysis of the phase 3 LITESPARK-005 trial showed that belzutifan demonstrated superior efficacy and safety outcomes vs everolimus across prespecified subgroups.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.